{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=23", "query": { "intervention": "Arm 1- Dose Escalation", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 959, "total_pages": 96, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T18:44:47.914Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04907539", "title": "A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "RXC004", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Denosumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Redx Pharma Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-11-08", "completion_date": "2024-04-02", "has_results": true, "last_update_posted_date": "2025-04-16", "last_synced_at": "2026-11-15T18:44:47.914Z", "location_count": 5, "location_summary": "Santa Rosa, California • Indianapolis, Indiana • Las Vegas, Nevada + 2 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Houston", "state": "Texas" }, { "city": "Kingswood", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04907539" }, { "nct_id": "NCT03179436", "title": "Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Quavonlimab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab/Quavonlimab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 415, "start_date": "2017-07-02", "completion_date": "2024-04-08", "has_results": true, "last_update_posted_date": "2025-04-08", "last_synced_at": "2026-11-15T18:44:47.914Z", "location_count": 5, "location_summary": "Gilbert, Arizona • Hackensack, New Jersey • Nashville, Tennessee + 2 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03179436" }, { "nct_id": "NCT01033409", "title": "Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pneumonia" ], "interventions": [ { "name": "Salmonella Typhi-vectored pneumonia vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Arizona State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 60, "start_date": "2009-08", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2011-11-02", "last_synced_at": "2026-11-15T18:44:47.914Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01033409" }, { "nct_id": "NCT02266745", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "CRPC", "mCRPC", "Metastatic Castrate-resistant Prostate Cancer", "PT-112", "Prostatic Neoplasms", "Genital Neoplasms, Male", "Urogenital Neoplasms", "Neoplasms by Site" ], "interventions": [ { "name": "PT-112 Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Promontory Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 109, "start_date": "2014-07", "completion_date": "2025-04-01", "has_results": false, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-11-15T18:44:47.914Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02266745" }, { "nct_id": "NCT03480646", "title": "ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "CPI-1205", "type": "DRUG" }, { "name": "Cobicistat", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Constellation Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 175, "start_date": "2017-11-15", "completion_date": "2021-02-03", "has_results": true, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-11-15T18:44:47.914Z", "location_count": 41, "location_summary": "Anchorage, Alaska • Beverly Hills, California • Duarte, California + 34 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03480646" }, { "nct_id": "NCT02356159", "title": "Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Hodgkin's Lymphoma", "Non-Hodgkin's Lymphoma", "Acute Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Conditioning chemotherapy", "type": "DRUG" }, { "name": "TMS", "type": "DRUG" }, { "name": "FLAG", "type": "DRUG" }, { "name": "EPOCH-F", "type": "DRUG" }, { "name": "Hematopoietic stem cell transplant", "type": "PROCEDURE" }, { "name": "Palifermin", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" }, { "name": "IV Saline", "type": "OTHER" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "MUGA", "type": "DIAGNOSTIC_TEST" }, { "name": "DEXA", "type": "DIAGNOSTIC_TEST" }, { "name": "CT chest", "type": "DIAGNOSTIC_TEST" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "BM aspirate", "type": "PROCEDURE" }, { "name": "BM biopsy", "type": "PROCEDURE" }, { "name": "Lumbar puncture", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2015-09-24", "completion_date": "2025-03-25", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-11-15T18:44:47.914Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02356159" }, { "nct_id": "NCT05419479", "title": "Switch Maintenance in Pancreatic", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Adenocarcinoma of the Pancreas", "Squamous Cell Carcinoma of Pancreas", "Adenosquamous Carcinoma of the Pancreas" ], "interventions": [ { "name": "ZIMBERELIMAB", "type": "DRUG" }, { "name": "DOMVANALIMAB", "type": "DRUG" }, { "name": "APX005M", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James Cleary, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2022-11-30", "completion_date": "2032-05-17", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-11-15T18:44:47.914Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05419479" }, { "nct_id": "NCT04776018", "title": "A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed and/or Refractory Multiple Myeloma (RRMM)" ], "interventions": [ { "name": "TAK-981", "type": "DRUG" }, { "name": "Mezagitamab", "type": "DRUG" }, { "name": "Daratumumab and Hyaluronidase-fihj", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2021-04-20", "completion_date": "2023-11-09", "has_results": true, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-11-15T18:44:47.914Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04776018" }, { "nct_id": "NCT01207076", "title": "AHN-12 Biodistribution in Advanced Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome", "Acute Lymphoblastic Leukemia", "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "90Y-AHN-12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 8, "start_date": "2013-12", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-11-15T18:44:47.914Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01207076" }, { "nct_id": "NCT06628310", "title": "A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "Telisotuzumab Adizutecan", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2024-12-13", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-11-15T18:44:47.914Z", "location_count": 8, "location_summary": "Duarte, California • Irvine, California • Santa Monica, California + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06628310" } ] }